Conclusions:
The results of this study allow us to conclude that low expression of MLH1 is associated with BRAF V600E mutations, RET/PTC rearrangements and transitions (IDH1 and NRAS) in patients with thyroid carcinoma. In addition, a significant relat…
ConclusionsThe TOSQ is the first described screening tool for identification of LEs designed specifically for SPBTs. It is simple to use and provides a valid, comprehensive and economic assessment followed by targeted treatment plan for each patient. By repeatedly using the TOSQ over the years, we can improve our ability to detect and give focused treatment to those who require assistance. Pediatr Blood Cancer © 2013 Wiley Periodicals, Inc. (Source: Pediatric Blood and Cancer)
View SourceCONCLUSIONS: Over-expression of Cx43 has inverse association with the grade of glioma. Therefore, increasing the expression of Cx43 can be beneficial for the treatment of glioma. We showed that, Cx43 is differentially modulated in two different glioma …
View SourceCONCLUSIONS: Polytherapy with VPA and LEV strongly contributes to seizure control to either of these as monotherapy. Use of VPA together with chemoradiation by temozolomide results in a 2 months longer survival of patients with GBM.Disclosure: Dr. Kerk…
View SourceCONCLUSIONS: Cranial CT scans performed in children are often normal, and findings infrequently change management in patients presenting with seizures, head trauma, and headache. Therefore, it may be safer to consider observation or MRI as alternatives…
View SourceCONCLUSIONS: Outcomes in elderly patients with proved glioblastoma are really improved by surgery, followed by chemoradiation if their clinical status allows it. And for patients with comorbidities or bad tumour location, we propose chemotherapy by tem…
View SourceCONCLUSIONS: In this case series, adult patients with recurrent HGGs had prolonged overall and post-recurrence survival. These results suggest bevacizumab may be an effective therapy in NF1 patients with recurrent HGGs. Based on these observations, evaluation of bevacizumab responses in sporadic glioblastomas with NF1 mutations is warranted.Disclosure: Dr. Theeler has nothing to disclose. Dr. Ellezam has nothing to disclose. Dr. Slopis has nothing to disclose. Dr. Loghin has nothing to disclose. Dr. De Groot has received personal compensation for activities with Genentech, Inc., VBL Therapeutics, and Merck & Co., Inc. Dr. De Groot has received research support from Sanofi-Aventis Pharmaceuticals, Inc., AstraZeneca Pharmaceuticals, and EMD Serono. (Source: Neurology)
MedWorm Sponsor Message: Have a look at The Cancer and Oncology Daily, the new cancer portal with all the latest cancer news and research powered by MedWorm, updated daily.
CONCLUSIONS: To our knowledge this is the first case repo of a patient with both oligodendroglioma and MS treated with Temozolomide with control of both diseases. This opens the potential for clinical trials with Temozolomide for patients with MS who f…
View Sourceby Renee D. Read, Tim R. Fenton, German G. Gomez, Jill Wykosky, Scott R. Vandenberg, Ivan Babic, Akio Iwanami, Huijun Yang, Webster K. Cavenee, Paul S. Mischel, Frank B. Furnari, John B. Thomas
Glioblastoma, the most common primary malignant brain…
View SourceCONCLUSIONS: Concurrent use of Dex with Bev increased rate of radiographic response to treatment without affecting duration of response showing a possible synergistic effect. Larger prospective studies are required to further study this effect.Disclosu…
View Source
